Express Pharma
OCTOBER 9, 2023
A study published in the journal Nature Communications has identified a new pathway that human immunodeficiency virus (HIV) uses to enter the nucleus of a healthy cell, where it can then replicate and go on to invade other cells. But how the viruses get past the protective membrane is not well understood and is the subject of much debate.
Express Pharma
AUGUST 13, 2023
A study published in the journal Nature Communications has identified a new pathway that human immunodeficiency virus (HIV) uses to enter the nucleus of a healthy cell, where it can then replicate and go on to invade other cells. But how the viruses get past the protective membrane is not well understood and is the subject of much debate.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MAY 27, 2022
Teams and Zoom became the backbone of communication and firms embraced new ways of working. However, if considered early in the drug development plan, compliance is by no means insurmountable and would be offset by the benefits of digital healthcare tools for patient engagement. About the interviewees.
Pulses
AUGUST 31, 2023
Table 1: Virtual Technology Platform: Pros and Cons Pros AR VR MR XR Metaverse Enhanced user experience/interaction √ √ Immersive and Engaging Experience √ √ Increased Collaboration and Communication √ √ √ Social interaction √ √ √ √ √ Used in training and simulation √ √ √ √ Enhanced Connectivity √ Creative Expression √ Cons Cybersickness AR VR MR XR (..)
pharmaphorum
APRIL 11, 2022
Delivering value for patients doesn’t start and end in our R&D labs; actions can be implemented across all stages of the drug development lifecycle to encourage and embrace a pro-innovation environment. The role of innovation in value-based healthcare.
FDA Law Blog: Biosimilars
NOVEMBER 2, 2023
The guidance describes elements that would be required of VCS bodies for recognition of standards they adopt: openness (with meaningful opportunities to participate), balance (broad range of stakeholders), due process, an appeals process, and consensus.
European Pharmaceutical Review
JUNE 24, 2022
But what are the key potential changes and how could they impact drug developers and manufacturers? He noted that within the proposals, there is likely to be a differentiation in incentives for drug development in the orphan and unmet medical need areas. Key areas of potential legislative change. Future outlook.
Expert insights. Personalized for you.
106 
Let's personalize your content